title: PET/Computed Tomography and Patient Outcomes in Melanoma.
abstract: The performance of fludeoxyglucose F 18 (FDG)-PET/computed tomography (CT) in the initial and follow-up evaluation of patients with melanoma is well established. Groups are beginning to investigate whether the inclusion of FDG-PET/CT into a staging or surveillance algorithm results in an improvement in patient outcome and whether such an imaging program would be cost-effective.
authors.affiliation: Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, 1400 Pressler - Unit 1483, Houston, TX 77030, USA; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler - Unit 1483, Houston, TX 77030, USA. Electronic address: eric.rohren@mdanderson.org.
authors.forename: Eric M
authors.initials: EM
authors.lastname: Rohren
mesh_terms: D000368:Aged; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000473:pathology*; D008875:Middle Aged; D064847:Multimodal Imaging / Q000379:methods / Q000401:mortality; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D063868:Patient Outcome Assessment; D049268:Positron-Emission Tomography / Q000379:methods* / Q000401:mortality; D011379:Prognosis; D019275:Radiopharmaceuticals; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology*; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed / Q000379:methods* / Q000401:mortality
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: Melanoma; Outcomes; PET/CT; Surveillance